Last10K.com

Angion Biomedica Corp. (ANGN) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

ANGN Quarterly Reports

Angion Biomedica Corp.

CIK: 1601485 Ticker: ANGN

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases

-- Ended the year with nearly $89M in cash and cash equivalents


Uniondale, NY – March 30, 2022
Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today reported its financial results for full year 2021.

“In 2022, we are focused on advancing Angion’s lead clinical development candidate ANG-3070 for the treatment of patients with primary proteinuric kidney diseases and continuing the enrollment of JUNIPER, our Phase 2 dose-finding study in focal segmental glomerular sclerosis and IgA nephropathy patients,” said Dr. Jay R. Venkatesan, Angion’s Chairman and Chief Executive Officer. “We also plan to advance ANG-3070 for the treatment of idiopathic pulmonary fibrosis and to file an IND by the end of the year in this population in need of additional approved therapies.”

Angion’s Strategic Objectives in 2022
Develop ANG-3070 for treatment of patients with primary proteinuric kidney diseases (PPKDs) including focal segmental glomerular sclerosis (FSGS) and IgA nephropathy (IgAN), which are the subject of Angion’s JUNIPER Phase 2 trial
Develop ANG-3070 for treatment of patients with idiopathic pulmonary fibrosis (IPF), with a planned IND filing in IPF by the end of 2022
Nominate a lead compound and initiate IND-enabling studies for one or more of the preclinical rho kinase 2 (ROCK2) or CYP11B2 (aldosterone synthase) inhibitor programs

Corporate News
Reported topline results from the Phase 3 trial of ANG-3777 for the treatment of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF) and an exploratory Phase 2 trial for the prevention of acute kidney injury (AKI) in patients undergoing cardiac surgery involving cardiopulmonary bypass who were thought to be at risk for AKI (CSA-AKI). While neither trial achieved statistical significance on its primary endpoint, Angion believes ANG-3777 demonstrated biologic activity in both trials. Angion continues to work with its partner Vifor Pharma on the process of closing out its analyses of data from these trials. Angion does not intend to continue the clinical development plan for ANG-3777 currently set forth in the Vifor License Agreement (“Vifor License”), which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF. Angion has no funds budgeted for additional clinical trials for ANG-3777.
Presented multiple posters at the American Society of Nephrology’s Kidney Week Conference on the activity of ANG-3070 in multiple models of renal fibrosis as well as a presentation on the design of JUNIPER, the Phase 2 trial of ANG-3070 in PPKD patients with FSGS and IgAN.
Held an ANG-3070 Virtual R&D Day on September 20, 2021, a recording of which is available on the Events & Presentations page of the company website.
Described in greater detail positive data from the Phase 1 healthy volunteer study of ANG-3070
Presented preclinical data in several models of kidney and lung fibrosis
Heard from experts in kidney fibrosis and lung fibrosis about the unmet medical needs in both indications
Ongoing progress on preclinical programs for a ROCK2 inhibitor and a CYP11B2 inhibitor.



The following information was filed by Angion Biomedica Corp. (ANGN) on Wednesday, March 30, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Angion Biomedica Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Angion Biomedica Corp..

Continue

Assess how Angion Biomedica Corp.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Angion Biomedica Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Shares
Income
Other
Inside Angion Biomedica Corp.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Operations And Comprehensive Loss
Condensed Consolidated Statements Of Stockholders' Equity (Deficit)
Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Parenthetical)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Schedule Of Accrued Expenses (Details)
Balance Sheet Components - Schedule Of Prepaid And Other Current Assets (Details)
Balance Sheet Components - Schedule Of Property And Equipment, Net (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Schedule Of Components Of Operating Lease Costs (Details)
Commitments And Contingencies - Schedule Of Maturities Of Financing Obligation (Details)
Commitments And Contingencies - Schedule Of Maturities Of Lease Liabilities (Details)
Commitments And Contingencies - Schedule Of Quantitative Information About Operating Leases (Details)
Commitments And Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)
Description Of The Business And Financial Condition
Description Of The Business And Financial Condition (Details)
Employee Benefit Plan
Employee Benefit Plan (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Fair Value Measurement Inputs And Valuation Techniques (Details)
Fair Value Measurements - Fair Value, Liabilities, Measured On Recurring Basis, Unobservable Input Reconciliation (Details)
Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details)
Income Taxes
Income Taxes (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Schedule Of Antidilutive Securities Excluded From Computation Of Net Loss Per Share (Details)
Net Loss Per Share - Schedule Of Net Loss Per Share, Basic And Diluted (Details)
Related Party Transactions
Related Party Transactions (Tables)
Related Party Transactions - Additional Information (Details)
Related Party Transactions - Nova Park Investment Activity (Details)
Revenue And Deferred Revenue
Revenue And Deferred Revenue (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Components Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Schedule Of Assumptions Used To Estimate Fair Value Of Stock Option Awards (Details)
Stock-Based Compensation - Schedule Of Rsu Information And Activity (Details)
Stock-Based Compensation - Schedule Of Share Option Activity (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Warrants
Warrants (Tables)
Warrants - Outstanding Warrants (Details)

Material Contracts, Statements, Certifications & more

Angion Biomedica Corp. provided additional information to their SEC Filing as exhibits

Ticker: ANGN
CIK: 1601485
Form Type: 10-Q Quarterly Report
Accession Number: 0001601485-22-000037
Submitted to the SEC: Mon May 16 2022 4:14:56 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/angn/0001601485-22-000037.htm